Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AdaptHealth (AHCO) EBITDA (2018 - 2026)

AdaptHealth has reported EBITDA over the past 8 years, most recently at $19.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 89.48% year-over-year to $19.2 million; the TTM value through Dec 2025 reached $452.4 million, down 25.45%, while the annual FY2025 figure was $452.5 million, 25.44% down from the prior year.
  • EBITDA for Q4 2025 was $19.2 million at AdaptHealth, down from $154.3 million in the prior quarter.
  • Over five years, EBITDA peaked at $182.7 million in Q4 2024 and troughed at -$370.7 million in Q3 2023.
  • A 5-year average of $87.5 million and a median of $131.3 million in 2021 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: surged 921.27% in 2021 and later tumbled 373.91% in 2023.
  • Year by year, EBITDA stood at $134.1 million in 2021, then fell by 11.22% to $119.0 million in 2022, then tumbled by 210.06% to -$131.0 million in 2023, then soared by 239.44% to $182.7 million in 2024, then tumbled by 89.48% to $19.2 million in 2025.
  • Business Quant data shows EBITDA for AHCO at $19.2 million in Q4 2025, $154.3 million in Q3 2025, and $166.5 million in Q2 2025.